Yazar "Kose, Fatih" seçeneğine göre listele
Listeleniyor 1 - 8 / 8
Sayfa Başına Sonuç
Sıralama seçenekleri
Öğe Antifungal Activities of Essential Oils Against Citrus Black Rot Disease Agent Alternaria alternata(Taylor & Francis Ltd, 2015) Soylu, E. Mine; Kose, FatihAntifungal effects of plant essential oils (Origanum onites L., Thymbra spicata L., Lavandula stoechas L. subsp. stoechas L., Foeniculum vulgare Mill. and Laurus nobilis L.) were investigated in vitro conditions against post-harvest fungal pathogen of Citrus, Alternaria alternata. O. onites and T. spicata essential oils exhibited the strongest antifungal activity against A. alternata by inhibiting completely mycelial growth of A.alternata at 20.0 and 80.0 mu g ml(-1) concentrations, respectively. Conidial germination and germ tube elongation of the pathogen was also completely inhibited by O. onites, T. spicata and F. vulgare essential oils used at the minimum concentrations of 10.0 mu g ml(-1). Light and scanning electron microscopic observations on fungal structures, exposed to volatile phase of themost efficient essential oils, revealed considerable structural deformations such as cytoplasmic coagulation, vacuolations and protoplast leakage. The plant essential oils showing potent fungitoxic efficacies may be recommended as a plant-based preservative in the management of fungal infestation of fruits and vegetables during storage.Öğe Antifungal Effects of Essential Oils on Mycelial Growth, Conidia Germination and Morphology of Hyphae of Gray Mold Disease Agent Botrytis cinerea(Kahramanmaras Sutcu Imam Univ Rektorlugu, 2023) Kose, Fatih; Soylu, Emine MineBotrytis cinerea, which causes gray mold disease, is a fungal disease agent with a wide host range, including citrus fruits. In this study, antifungal effects of plant essential oils obtained from different thyme species (Origanum onites L., Origanum syriacum Holm., Thymbra spicata L.) and fennel (Foeniculum vulgare Mill.) in vapor phase were investigated on mycelial growth, conidia germination and morphology of hyphae of B. cinerea in vitro conditions. Among the essential oils, the highest antifungal activity (100% inhibition) was detected at the dose of 10 mu g mL-1 of O. onites and O. syriacum essential oils, and these applications were followed by T. spicata at a dose of 40 mu g mL-1 and F. vulgare essential oil at a relatively higher dose (120 mu g mL-1) used. The effectiveness of essential oils at doses that completely inhibit mycelial growth were determined as fungicidal. All essential oils tested completely inhibited the germination of fungal conidia at the dose of 10 mu g mL-1. In scanning and light microscopy studies, it has been observed that essential oils cause serious deteriorations such as vesiculation, cytoplasmic coagulation and lysis on fungal mycelium and conidia at minimum inhibition concentrations determined. Microscope observation results showed that the antifungal activities were due to the morphological deteriorations caused by the essential oils on the fungal hyphae and conidia. Overall results showed that essential oils of thyme species have the potential to be used as environmental friendly biofungicide alternative to chemicals against fungal diseases in stored products.Öğe Can serial monitoring of serum Vascular Endothelial Growth Factor (VEGF), Nitric Oxide (NO), and Angiotensin II (ANGII) levels have predictive role during Bevacizumab treatment?(Int Scientific Information, Inc, 2014) Sumbul, Ahmet Taner; Disel, Umut; Sezgin, Nurzen; Sezer, Ahmet; Kose, Fatih; Besen, Ali Ayberk; Sumbul, ZehraBackground: Standard treatment of colorectal cancer includes both cytostatic chemotherapy and targeted therapies. Bevacizumab, targeting the VEGF receptor, is one of the primary targeted therapies that achieve better response rate and survival rate as compared to combination chemotherapy. To the best of our knowledge, there is no established single marker that can be used as a predictive marker in bevacizumab therapy. Material/Methods: We enrolled 24 patients with the diagnosis of metastatic colorectal cancer in our study. During the study, 2 blood samples were drawn from patients before the first cycle and after the sixth cycle of bevacizumab therapy. Serum levels of VEGF, ANG II, and NO were recorded. Results: While the change across VEGF levels was found to be a statistically significant decreasing trend (p=0.009), this decrease was not found to be correlated with treatment response and hypertension development. Additionally, no statistically significant difference was found in terms of NO and ANG II levels. Conclusions: This study showed a significant decrease in serum VEGF, but failed to show a significant change in NO and ANG II levels during bevacizumab treatment. Although no significant correlation was found between the presence of hypertension and markers, most patients (83%) had an increase in their blood pressure. Our results suggest that dynamic monitoring of NO and ANG II, along with VEGF, may not be useful as predictive markers for bevacizumab treatment in colorectal cancer.Öğe Clinicohistopathological features and treatment outcomes in testicular lymphomas: A single center experience.(Amer Soc Clinical Oncology, 2018) Sedef, Ali Murat; Kocer, Nazim Emrah; Besen, Ali Ayberk; Mertsoylu, Huseyin; Sezer, Ahmet; Sumbul, Ahmet Taner; Kose, Fatih[Abstract Not Available]Öğe Concurrent Chemoradiotherapy with Vinorelbine plus Split-Dose Cisplatin may be an Option in Inoperable Stage III Non-Small Cell Lung Cancer: A Single-Center Experience(Int Scientific Information, Inc, 2015) Mertsoylu, Huseyin; Kose, Fatih; Sumbul, Ahmet Taner; Sedef, Ali Murat; Dogan, Ozlem; Besen, Ali Ayberk; Parlak, CemBackground: Concurrent chemoradiotherapy is the current standard treatment for inoperable stage III non-small cell lung cancer (NSCLC). In this study we aimed to investigate the efficacy and toxicity of CCRT with split dose of cisplatin (30 mg/m(2)) and vinorelbine (20 mg/m(2)) in patients with inoperable stage III NSCLC followed in our oncology clinic. Material/Methods: Medical records of 97 patients with inoperable stage III NSCLC treated with concurrent chemoradiotherapy with cisplatin-vinorelbine were retrospectively analyzed. Cisplatin (30 mg/m(2)) and vinorelbine (20 mg/m(2)) were administered on days 1, 8, 22, and 29 during radiotherapy. Two cycles of consolidation chemotherapy were given. All patient data, including pathological, clinical, radiological, biochemical, and hematological data, were assessed retrospectively using our database system. Results: Our study included 97 unresectable stage III NSCLC patients who were treated with CCRT. Median age was 58 years old (range 39-75) and 87 (89.7%) of the patients were men. ECOG performance score was 0-1 in 93 patients (95.9%). Squamous histology, the most common histology, was diagnosed in 46 patients (47.4%). Median follow-up time was 23.8 months. Median progression-free survival (PFS) and median overall survival time (OS) were 10.3 months and 17.8 months, respectively. Objective response rate and clinical benefit rate were 75.3% and 83.5%, respectively. Distant and local relapse rate were 57.1% and 42.9%, respectively. Hematological and non-hematological grade 3-4 toxicities were seen in 13 (13.4%) and 16 (16.5%) patients, respectively. Six (6.1%) patients died due to toxicity. Conclusions: The results of this study suggest that split-dose cisplatin may offer fewer grade III-IV toxicities without sacrificing efficacy and could be an option in patients with inoperable stage III NSCLC during CCRT. Similar to past studies, despite high response rate during CCRT, distant relapse is the major parameter that influences patient survival in long-term in NSCLC.Öğe Gemcitabine plus Platinum Combination Chemotherapy in Patients with Metastatic Cancer who suffer from Severe and Irreversible Hepatic Impairment: A Single Center Experience(H G E Update Medical Publishing S A, 2014) Sezer, Ahmet; Sumbul, Ahmet Taner; Abali, Huseyin; Mertsoylu, Huseyin; Muallaoglu, Sadik; Kose, Fatih; Ozyilkan, OzgurThere is limited information on chemotherapeutic agent doses suitable for patients with metastatic cancer who suffer from and irreversible hepatic impairment and who could potentially benefit from chemotherapy and on their results. In this retrospective study, we aimed to share our center's experience of Gemcitabine + Platinum Combination chemotherapy in these patients. Data of 13 patients matching the criteria were analyzed. In our study the patients were treated with a dose of Gemcitabine + Platinum Combination, 50% of the original dose and the dose was increased gradually on the following days. Thirteen of one patient was given Gemcitabine & Carboplatin protocol and the others were given Gemcitabine & Cisplatin. In 42 chemotherapy cycles in total grade 3-4 thrombocytopenia occure after 7 cycles, grade 3-4 neutropenia was not observed While liver functions in 8 patients improved slightly, no change was observed in 2 patients and in 3 patients they deteriorated. Total survival period was calculate as 3.78 (95CI%: 0,17-7.54) months. As a consequence Gemcitabine + Platinum Combination chemotherapy in patients with metastatic cancer who suffer from severe and irreversible hepatic impairment can be implemented when clinical benefits are expected.Öğe High Pretreatment Neutrophil-Lymphocyte Ratio: A Poor Prognostic Factor for Stage III Non-Small Cell Lung Cancer Patients(Elsevier Science Inc, 2015) Sumbul, Ahmet T.; Batmaci, Celal; Ucar, Edip; Kose, Fatih; Sedef, Ali M.; Yildirim, Berna; Mertsoylu, Huseyin[Abstract Not Available]Öğe Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel(Springer, 2014) Sumbul, Ahmet Taner; Sezer, Ahmet; Abali, Huseyin; Kose, Fatih; Gultepe, Ilhami; Mertsoylu, Huseyin; Muallaoglu, SadikThe neutrophil-to-lymphocyte ratio (NLR) is a marker of systemic inflammatory response and evidences for the relationship between NLR and the response to treatment gradually increases in cancer patients. In this study, we aimed to investigate the effect of the pretreatment NLR and other factors related to the patient on predicting the outcome of docetaxel + prednisone chemotherapy in prostate cancer patients who become castration resistant. Thirty-three metastatic castration-resistant prostate cancer patients those who were treated between 2009 and 2013 were included in our study. All data of the patients, including pathological, clinical, radiological, biochemical and hematological data, were assessed retrospectively using our database system. The median progression-free survival (PFS) was determined as 23.9 months (range 0.36-118.7) with androgen suppression therapy and 9.5 months (range 1.7-39.4) with docetaxel + prednisone therapy. NLR was found to be correlated with only posttreatment psa levels. In the NLR a parts per thousand currency sign3 group, the PSA levels were statistically significantly lower than the other group (r = 0.002). Furthermore, the relationships between the clinical response and PFS and the other pretreatment parameters of the patients were evaluated in order to predict which group would respond better to docetaxel + prednisone therapy after becoming androgen resistant. No relationship was found between any of the parameters and the response to therapy. Although NLR was found effective in predicting the PSA response in docetaxel + prednisone therapy, neither NLR nor any other clinical parameter was found effective in predicting the outcome and the role of NLR in the future of CRPC is questionable.
